Septerna (NASDAQ:SEPN – Get Free Report) was downgraded by Wells Fargo & Company from an “overweight” rating to an “equal weight” rating in a report issued on Tuesday,Briefing.com Automated Import reports. They currently have a $14.00 target price on the stock. Wells Fargo & Company‘s price target points to a potential upside of 8.02% from the company’s current price.
Other equities research analysts also recently issued reports about the company. JPMorgan Chase & Co. started coverage on Septerna in a research note on Tuesday, November 19th. They set an “overweight” rating and a $38.00 price target for the company. Cantor Fitzgerald restated an “overweight” rating and set a $50.00 price target on shares of Septerna in a research note on Tuesday, February 11th. Finally, TD Cowen started coverage on Septerna in a research note on Tuesday, November 19th. They set a “buy” rating for the company.
Get Our Latest Stock Analysis on SEPN
Septerna Stock Up 12.2 %
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. RA Capital Management L.P. bought a new position in shares of Septerna during the 4th quarter valued at approximately $160,205,000. TRV GP V LLC bought a new position in shares of Septerna during the 4th quarter valued at approximately $142,337,000. TRV GP VI LLC bought a new position in shares of Septerna during the 4th quarter valued at approximately $72,191,000. Samsara BioCapital LLC bought a new position in shares of Septerna during the 4th quarter valued at approximately $63,399,000. Finally, Driehaus Capital Management LLC bought a new position in shares of Septerna during the 4th quarter valued at approximately $59,301,000.
About Septerna
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
See Also
- Five stocks we like better than Septerna
- What Are Dividend Champions? How to Invest in the Champions
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- Business Services Stocks Investing
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
- Consumer Staples Stocks, Explained
- Analysts See Buying Opportunity in NVIDIA Before Earnings
Receive News & Ratings for Septerna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Septerna and related companies with MarketBeat.com's FREE daily email newsletter.